SPC Life Sciences Ltd. IPO Details
SPC Life Sciences was founded on June 15, 2005, with a focus on research and development-driven chemical manufacturing. The company is a manufacturer of advanced intermediates for certain key active pharmaceutical ingredients, including pentoxifylline, amiodarone HCl, cilostazol, trazodone, tramadol, and paroxetine. It specializes in chemistries involving long-chain multi-stage reactions.
| Bidding Dates |
|---|
| To Be Announced |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 8.9 M | - | - | ₹3,000.0 M | DRHP DOC |
SPC Life Sciences Ltd. issue details
SPC Life Sciences Ltd. has 8.9 M shares on offer
SPC Life Sciences Ltd. IPO issue size is ₹ 3,000.0 M
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
SPC Life Sciences Ltd. IMPORTANT IPO DATES
| Issue Open Date | - |
| Issue close Date | - |
| Allotment Date | - |
| Refund Date | - |
| Demat Account Credit Date | - |
| Listing Date | - |
| Listing on Exchange(s) | NSE and BSE |
SPC Life Sciences Ltd. NUMBER OF SHARES ON OFFER
SPC Life Sciences Ltd. FINANCIALS
| Period | Net Profit (Rs in millions) | Revenue from Operations (Rs in millions) | Cash Flow from Operations (Rs in millions) | Free Cash Flow (Rs in millions) |
| H1FY23 | 101.1 | 879.1 | 40.1 | -126.5 |
| H1FY22 | 98.7 | 698.4 | 25.0 | -107.8 |
| FY22 | 192.3 | 1,456.4 | 131.1 | -182.8 |
| FY21 | 166.7 | 1,329.5 | 133.7 | 55.8 |
| FY20 | 103.8 | 1,209.3 | 206.0 | 79.5 |
SPC Life Sciences Ltd. INFORMATION ON IPO ISSUE
About SPC Life Sciences Ltd.
SPC Life Sciences was founded on June 15, 2005, with a focus on research and development-driven chemical manufacturing. The company is a manufacturer of advanced intermediates for certain key active pharmaceutical ingredients, including pentoxifylline, amiodarone HCl, cilostazol, trazodone, tramadol, and paroxetine. It specializes in chemistries involving long-chain multi-stage reactions.
Object of the Issue
- Repayment/prepayment of certain outstanding borrowings availed by the company
- Funding of capital expenditure requirements of the company towards setting up phase-2 at the Dahej Facility to expand the product offerings of pharmaceutical intermediates
- Funding working capital requirements
- General corporate purposes
SPC Life Sciences Ltd. - PROMOTERS
| Name |
|---|
| Snehal Ravjibhai Patel |
SPC Life Sciences Ltd. Strengths
Diversified portfolio
The company has a strong and diversified portfolio of pharma intermediates and KSMs catering to growing therapeutic areas
Diversified customer base
The company's customers comprise of domestic and international pharmaceutical companies in Europe, China, Israel, North America and South America
High entry barriers
The complex manufacturing process, long customer approval cycles, and strict compliance requirements create high entry barriers in the industry
SPC Life Sciences Ltd. Risks
Dependent on few products
The company's revenue is heavily dependent on a few key products, such as intermediates for pentoxifylline and amiodaroneHCL
Pending tax proceedings
There are pending tax proceedings against the company and certain directors. Any adverse decision in such proceedings may render the company liable to liabilities/penalties and may adversely affect the business
IPO FAQs
The promoter of the company is Snehal Ravjibhai Patel.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.